REGN vs. VRTX, BMY, SNY, GSK, ZTS, TAK, RPRX, ABT, BGNE, and CTLT
Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Zoetis (ZTS), Takeda Pharmaceutical (TAK), Royalty Pharma (RPRX), Abbott Laboratories (ABT), BeiGene (BGNE), and Catalent (CTLT). These companies are all part of the "medical" sector.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Regeneron Pharmaceuticals presently has a consensus price target of $977.77, indicating a potential upside of 10.71%. Vertex Pharmaceuticals has a consensus price target of $429.45, indicating a potential upside of 8.04%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Vertex Pharmaceuticals.
In the previous week, Regeneron Pharmaceuticals had 4 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 22 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.73 beat Regeneron Pharmaceuticals' score of 0.68 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Vertex Pharmaceuticals received 59 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 66.58% of users gave Regeneron Pharmaceuticals an outperform vote.
Vertex Pharmaceuticals has a net margin of 36.68% compared to Regeneron Pharmaceuticals' net margin of 30.14%. Vertex Pharmaceuticals' return on equity of 21.91% beat Regeneron Pharmaceuticals' return on equity.
Regeneron Pharmaceuticals has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.
Summary
Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Regeneron Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regeneron Pharmaceuticals Competitors List
Related Companies and Tools
